Where does the money go to? Cost analysis of gynecological patients with a benign condition.

<h4>Objectives</h4>The impact of benign gynecological conditions on life of women and on costs for the society is high. The purpose of this study is to gain knowledge and understanding of costs of the treatment of these disorders in order to be able to improve the clinical care processes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kristiina Pynnä, Pirjo Räsänen, Risto P Roine, Piia Vuorela, Harri Sintonen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5c760ed12d0f41058e62f628a9a1f7ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c760ed12d0f41058e62f628a9a1f7ab
record_format	dspace
spelling	oai:doaj.org-article:5c760ed12d0f41058e62f628a9a1f7ab2021-12-02T20:09:22ZWhere does the money go to? Cost analysis of gynecological patients with a benign condition.1932-620310.1371/journal.pone.0254124https://doaj.org/article/5c760ed12d0f41058e62f628a9a1f7ab2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254124https://doaj.org/toc/1932-6203<h4>Objectives</h4>The impact of benign gynecological conditions on life of women and on costs for the society is high. The purpose of this study is to gain knowledge and understanding of costs of the treatment of these disorders in order to be able to improve the clinical care processes, gain insight into feasible savings opportunities and to allocate funds wisely.<h4>Methods</h4>The healthcare processes of 311 women attending university or community hospitals in the Helsinki and Uusimaa Hospital District between June 2012 and August 2013 due to a benign gynecological condition were followed up for two years and treatment costs analysed.<h4>Results</h4>Total direct hospital costs averaged 689€ at six months and 2194€ at two years. The most expensive treatment was that of uterine fibroids in the short term and that of endometriosis and fibroids later on. Costs did not depend on hospital size. Surgical operations caused nearly half of hospital costs. Productivity loss caused biggest expenses outside of the hospital. LNG-IUD (levonorgestrel-releasing intrauterine device) accounted for the largest pharmaceutical costs for patients. Hospital treatment was associated with a reduced need for outpatient services during follow-up.<h4>Conclusions</h4>A majority of direct hospital costs arise over time. This stresses the need for prolonged healthcare management. To control costs, the need for repetitive doctors' appointments, monitoring tests, and ward treatments should be carefully evaluated. Procedures not needing an operation theatre (for example hysteroscopy for polypectomy), should be done ambulatorily.Kristiina PynnäPirjo RäsänenRisto P RoinePiia VuorelaHarri SintonenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254124 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kristiina Pynnä Pirjo Räsänen Risto P Roine Piia Vuorela Harri Sintonen Where does the money go to? Cost analysis of gynecological patients with a benign condition.
description	<h4>Objectives</h4>The impact of benign gynecological conditions on life of women and on costs for the society is high. The purpose of this study is to gain knowledge and understanding of costs of the treatment of these disorders in order to be able to improve the clinical care processes, gain insight into feasible savings opportunities and to allocate funds wisely.<h4>Methods</h4>The healthcare processes of 311 women attending university or community hospitals in the Helsinki and Uusimaa Hospital District between June 2012 and August 2013 due to a benign gynecological condition were followed up for two years and treatment costs analysed.<h4>Results</h4>Total direct hospital costs averaged 689€ at six months and 2194€ at two years. The most expensive treatment was that of uterine fibroids in the short term and that of endometriosis and fibroids later on. Costs did not depend on hospital size. Surgical operations caused nearly half of hospital costs. Productivity loss caused biggest expenses outside of the hospital. LNG-IUD (levonorgestrel-releasing intrauterine device) accounted for the largest pharmaceutical costs for patients. Hospital treatment was associated with a reduced need for outpatient services during follow-up.<h4>Conclusions</h4>A majority of direct hospital costs arise over time. This stresses the need for prolonged healthcare management. To control costs, the need for repetitive doctors' appointments, monitoring tests, and ward treatments should be carefully evaluated. Procedures not needing an operation theatre (for example hysteroscopy for polypectomy), should be done ambulatorily.
format	article
author	Kristiina Pynnä Pirjo Räsänen Risto P Roine Piia Vuorela Harri Sintonen
author_facet	Kristiina Pynnä Pirjo Räsänen Risto P Roine Piia Vuorela Harri Sintonen
author_sort	Kristiina Pynnä
title	Where does the money go to? Cost analysis of gynecological patients with a benign condition.
title_short	Where does the money go to? Cost analysis of gynecological patients with a benign condition.
title_full	Where does the money go to? Cost analysis of gynecological patients with a benign condition.
title_fullStr	Where does the money go to? Cost analysis of gynecological patients with a benign condition.
title_full_unstemmed	Where does the money go to? Cost analysis of gynecological patients with a benign condition.
title_sort	where does the money go to? cost analysis of gynecological patients with a benign condition.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/5c760ed12d0f41058e62f628a9a1f7ab
work_keys_str_mv	AT kristiinapynna wheredoesthemoneygotocostanalysisofgynecologicalpatientswithabenigncondition AT pirjorasanen wheredoesthemoneygotocostanalysisofgynecologicalpatientswithabenigncondition AT ristoproine wheredoesthemoneygotocostanalysisofgynecologicalpatientswithabenigncondition AT piiavuorela wheredoesthemoneygotocostanalysisofgynecologicalpatientswithabenigncondition AT harrisintonen wheredoesthemoneygotocostanalysisofgynecologicalpatientswithabenigncondition
_version_	1718375062633971712

Where does the money go to? Cost analysis of gynecological patients with a benign condition.

Ejemplares similares